Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hana Pharm Co., Ltd. (293480:KRX), powered by AI.
Hana Pharm Co., Ltd. is currently trading at ₩9,260. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hana Pharm Co., Ltd. on Alpha Lenz.
Hana Pharm Co., Ltd.'s P/E ratio is 18.7.
“Hana Pharm Co., Ltd. trades at a P/E of 18.7 (fair value) with modest ROE of 2.8%.”
Ask for details →Hana Pharm Co., Ltd. is a dynamic pharmaceutical company primarily engaged in the research, development, production, and distribution of a broad range of medical products. Focused on addressing various therapeutic needs, the company offers products spanning sectors such as oncology, anesthetics, and cardiovascular treatments. Notably, Hana Pharm is recognized for its innovative drug delivery systems and cutting-edge formulation techniques, which enhance the efficacy and safety of its pharmaceutical offerings. Valued for its commitment to quality and innovation, Hana Pharm actively contributes to the healthcare industry's evolution by continually developing new treatment options and improving existing medications. The market significance of Hana Pharm can be attributed to its strategic investments in research and development, which not only bolster its product pipeline but also reinforce its competitive edge in the pharmaceutical market. Additionally, its range of products caters to diverse healthcare markets, both domestically and internationally, helping improve patient outcomes and accessibility to advanced medications.
“Hana Pharm Co., Ltd. trades at a P/E of 18.7 (fair value) with modest ROE of 2.8%.”
Ask for details →Hana Pharm Co., Ltd. (ticker: 293480) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $164.6B.
The current price is ₩9,260 with a P/E ratio of 18.75x and P/B of 0.53x.
ROE is 2.82% and operating margin is 10.78%. Annual revenue is $239.5B.